Clinical trial / 2015
Green tea extract was generally tolerated but increased liver enzyme elevations
In a randomized trial, 1,075 postmenopausal women took daily green tea extract containing 843 mg epigallocatechin-3-gallate or placebo for one year. Overall adverse event rates were similar between groups (75.6% vs. 72.8%). However, the extract group experienced more nausea (P < 0.001) and significantly more alanine aminotransferase elevations (6.7% vs. 0.7%, P < 0.001), including 1.3% with serious related events.
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 1,075 postmenopausal women at risk for breast cancer
- What was measured
- Adverse events and liver enzyme elevations
THE PAPER
The safety of green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial.
Dostal AM, Samavat H, Bedell S, Torkelson C, Wang R, Swenson K, Le C, Wu AH, Ursin G, Yuan JM, Kurzer MS. Food Chem Toxicol, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.